Characterization of Monoclonal Antibody LpMab-3 Recognizing Sialylated Glycopeptide of Podoplanin

Podoplanin (PDPN/Aggrus/T1α/gp36/OTS-8), a type I transmembrane sialoglycoprotein, is involved in platelet aggregation, cell invasion, and cancer metastasis. Podoplanin expression in cancer cells or cancer-associated fibroblasts was reported to be involved in poor prognosis of several cancers. Furthermore, podoplanin is expressed in lymphatic endothelial cells or lung type I alveolar cells. Although many anti-podoplanin monoclonal antibodies (MAbs), such as NZ-1 and D2–40, have been established, almost all anti-podoplanin MAbs are produced against a platelet aggregation-inducing (PLAG) domain. In this study, we produced and characterized a novel anti-podoplanin monoclonal antibody, LpMab-3, the epitope of which is a sialylated glycopeptide of podoplanin. We identified the minimum epitope of LpMab-3 as Thr76–Glu81 of human podoplanin, which is different from PLAG domain, using Western blot analysis and flow cytometry. Immunohistochemical analysis showed that LpMab-3 is useful for detecting lung type I alveolar cells and lymphatic endothelial cells. Because LpMab-3 detects only sialylated podoplanin, it could be useful for uncovering the physiological function of sialylated human podoplanin.

[1]  Y. Yamaguchi,et al.  A platform of C-type lectin-like receptor CLEC-2 for binding O-glycosylated podoplanin and nonglycosylated rhodocytin. , 2014, Structure.

[2]  Robert P. Jenkins,et al.  Dendritic Cells Control Fibroblastic Reticular Network Tension and Lymph Node Expansion , 2014, Nature.

[3]  K. Kikuchi,et al.  Podoplanin expressing cancer-associated fibroblasts in oral cancer , 2014, Tumor Biology.

[4]  Y. Kato,et al.  A Cancer-specific Monoclonal Antibody Recognizes the Aberrantly Glycosylated Podoplanin , 2014, Scientific Reports.

[5]  Junichi Takagi,et al.  PA tag: a versatile protein tagging system using a super high affinity antibody against a dodecapeptide derived from human podoplanin. , 2014, Protein expression and purification.

[6]  Shigeo Sato,et al.  Expression of Aggrus/podoplanin in bladder cancer and its role in pulmonary metastasis , 2013, International journal of cancer.

[7]  Y. Kato.  Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas , 2014, Brain Tumor Pathology.

[8]  K. Ohuchida,et al.  Podoplanin expression in cancer-associated fibroblasts enhances tumor progression of invasive ductal carcinoma of the pancreas , 2013, Molecular Cancer.

[9]  S. Coughlin,et al.  Podoplanin maintains high endothelial venule integrity by interacting with platelet CLEC-2 , 2013, Nature.

[10]  Shigeo Sato,et al.  Platelets Promote Tumor Growth and Metastasis via Direct Interaction between Aggrus/Podoplanin and CLEC-2 , 2013, PloS one.

[11]  Y. Sekido,et al.  A Novel Targeting Therapy of Malignant Mesothelioma Using Anti-Podoplanin Antibody , 2013, The Journal of Immunology.

[12]  I. Pastan,et al.  Recombinant anti‐podoplanin (NZ‐1) immunotoxin for the treatment of malignant brain tumors , 2013, International journal of cancer.

[13]  S. Schoppmann,et al.  Podoplanin expressing cancer associated fibroblasts are associated with unfavourable prognosis in adenocarcinoma of the esophagus , 2012, Clinical & Experimental Metastasis.

[14]  M. Fukayama,et al.  Chimeric anti‐podoplanin antibody suppresses tumor metastasis through neutralization and antibody‐dependent cellular cytotoxicity , 2012, Cancer science.

[15]  V. Kuchroo,et al.  Podoplanin-Rich Stromal Networks Induce Dendritic Cell Motility via Activation of the C-type Lectin Receptor CLEC-2 , 2012, Immunity.

[16]  Jenna M. Sullivan,et al.  Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. , 2011, Immunity.

[17]  T. Owczarek,et al.  Podoplanin expression by cancer‐associated fibroblasts predicts poor outcome in invasive ductal breast carcinoma , 2011, Histopathology.

[18]  Shigeo Sato,et al.  Prevention of hematogenous metastasis by neutralizing mice and its chimeric anti‐Aggrus/podoplanin antibodies , 2011, Cancer science.

[19]  M. Fukayama,et al.  Podoplanin is regulated by AP-1 and promotes platelet aggregation and cell migration in osteosarcoma. , 2011, The American journal of pathology.

[20]  A. Ochiai,et al.  Podoplanin-positive fibroblasts enhance lung adenocarcinoma tumor formation: podoplanin in fibroblast functions for tumor progression. , 2011, Cancer research.

[21]  W. Tian,et al.  Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation. , 2011, Biochemical and biophysical research communications.

[22]  S. Keir,et al.  Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas. , 2010, Nuclear medicine and biology.

[23]  M. Lu,et al.  Platelets regulate lymphatic vascular development through CLEC-2-SLP-76 signaling. , 2010, Blood.

[24]  A. Ochiai,et al.  Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinoma , 2008, International journal of cancer.

[25]  J. Price,et al.  Characterization of anti-podoplanin monoclonal antibodies: critical epitopes for neutralizing the interaction between podoplanin and CLEC-2. , 2008, Hybridoma.

[26]  Hiromi Ito,et al.  Molecular analysis of the pathophysiological binding of the platelet aggregation‐inducing factor podoplanin to the C‐type lectin‐like receptor CLEC‐2 , 2007, Cancer science.

[27]  K. Mishima,et al.  Involvement of the Snake Toxin Receptor CLEC-2, in Podoplanin-mediated Platelet Activation, by Cancer Cells*♦ , 2007, Journal of Biological Chemistry.

[28]  T. Yoshimoto,et al.  Immunohistochemical detection of the lymphatic marker podoplanin in diverse types of human cancer cells using a novel antibody. , 2007, International journal of oncology.

[29]  A. Kuno,et al.  Functional glycosylation of human podoplanin: Glycan structure of platelet aggregation‐inducing factor , 2007, FEBS letters.

[30]  A. Kuno,et al.  Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain. , 2006, Biochemical and biophysical research communications.

[31]  T. Kitano,et al.  Conservation of a platelet activating domain of Aggrus/podoplanin as a platelet aggregation-inducing factor. , 2006, Gene.

[32]  Diane D. Liu,et al.  Overexpression of podoplanin in oral cancer and its association with poor clinical outcome , 2006, Cancer.

[33]  T. Tsuruo,et al.  Podoplanin expression in primary central nervous system germ cell tumors: a useful histological marker for the diagnosis of germinoma , 2006, Acta Neuropathologica.

[34]  K. Mishima,et al.  Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression , 2006, Acta Neuropathologica.

[35]  T. Tsuruo,et al.  Enhanced Expression of Aggrus (T1alpha/Podoplanin), a Platelet-Aggregation-Inducing Factor in Lung Squamous Cell Carcinoma , 2005, Tumor Biology.

[36]  M. Detmar,et al.  Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. , 2005, The American journal of pathology.

[37]  M. Quintanilla,et al.  Characterization of human PA2.26 antigen (T1α–2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas , 2005, International journal of cancer.

[38]  T. Tsuruo,et al.  Aggrus: a diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors , 2004, Oncogene.

[39]  T. Tsuruo,et al.  Functional Sialylated O-Glycan to Platelet Aggregation on Aggrus (T1α/Podoplanin) Molecules Expressed in Chinese Hamster Ovary Cells* , 2004, Journal of Biological Chemistry.

[40]  T. Tsuruo,et al.  Molecular Identification of Aggrus/T1α as a Platelet Aggregation-inducing Factor Expressed in Colorectal Tumors* , 2003, Journal of Biological Chemistry.

[41]  H. Yeger,et al.  Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumours , 1999, British Journal of Cancer.

[42]  D. Kerjaschki,et al.  Epitope-specific antibodies to the 43-kD glomerular membrane protein podoplanin cause proteinuria and rapid flattening of podocytes. , 1998, Journal of the American Society of Nephrology : JASN.

[43]  G. Schaffner,et al.  Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. , 1997, American Journal of Pathology.